한글목차

펜니들 세계 시장은 2030년까지 48억 달러에 이를 전망

2023년에 26억 달러로 추정되는 펜니들 세계 시장은 2023-2030년간 CAGR 9.2%로 성장하여 2030년에는 48억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 표준 펜니들은 CAGR 7.3%를 나타내고, 분석 기간 종료시에는 26억 달러에 이를 것으로 예측됩니다. 안전 펜니들 분야의 성장률은 분석 기간에 CAGR 11.9%로 추정됩니다.

미국 시장은 8억 3,650만 달러, 중국은 CAGR 10.3%로 성장 예측

미국의 펜니들 시장은 2023년에 8억 3,650만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 10.3%로 성장을 지속하여, 2030년에는 3억 8,170만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 8.0%와 8.2%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 8.4%를 나타낼 전망입니다.

세계 펜니들 시장 - 주요 동향 및 촉진요인 요약

펜니들은 인슐린, 성장 호르몬 및 기타 치료제와 같은 약물을 투여하기 위해 주사 펜에 사용되는 중요한 부품입니다. 이 주사 바늘은 펜형 장치에 부착하도록 설계되어 피하 주사를 할 수 있는 편리하고 정확한 방법을 제공합니다. 펜니들은 다양한 길이와 게이지로 제공되며, 환자와 의료 서비스 제공업체는 다양한 주사 부위와 환자의 필요에 따라 가장 적합한 바늘을 선택할 수 있습니다. 펜니들 디자인은 주사 시 통증과 불편함을 최소화하는 데 중점을 두었으며, 초박형 벽, 얇은 팁, 윤활 코팅 등의 특징을 가지고 있습니다. 따라서 펜니들은 정기적으로 인슐린을 투여해야 하는 당뇨병 환자 등 주사를 자주 맞아야 하는 환자에게 특히 적합합니다.

기술의 발전으로 펜니들의 디자인과 기능이 크게 개선되었습니다. 최신 펜니들에는 날카로움을 개선하고 찌르는 입력을 감소시키는 첨단 제조 기술이 적용되어 통증이 덜한 주사가 가능해졌습니다. 바늘에 찔리는 부상을 방지하는 보호막이 내장된 안전한 펜니들 등의 혁신으로 환자와 의료진 모두의 안전이 향상되었습니다. 또한, 더 짧고 가느다란 주사바늘의 개발은 주사에 대한 두려움을 없애고 보다 편안한 주사를 가능하게 하여 치료 요법에 대한 순응도를 높이고 있습니다. 고품질 소재의 사용은 펜니들의 내구성과 신뢰성을 보장하고 매번 사용할 때마다 안정적인 성능을 발휘할 수 있도록 합니다. 이러한 발전으로 인해 펜니들은 다양한 치료 분야에서 채택이 확대되고 있으며, 약물 전달을 위한 선호되는 선택이 되고 있습니다.

펜 니들 시장의 성장은 당뇨병 유병률 증가, 약물 자가 투여 증가, 바늘 기술의 발전 등 여러 가지 요인에 의해 주도되고 있습니다. 전 세계 당뇨병 환자 증가는 펜침을 포함한 인슐린 전달 장치에 대한 수요를 크게 증가시켰습니다. 환자의 편의성과 정기적인 치료의 필요성으로 인해 약물 자가투여를 선호하는 추세는 시장 성장을 더욱 촉진하고 있습니다. 안전성과 초미세 펜니들 개발과 같은 기술적 발전으로 인해 주사의 안전성과 편의성이 향상되어 환자들에게 널리 보급되고 있습니다. 또한, 다양한 길이와 게이지의 펜침이 출시되면서 환자들의 다양한 요구에 맞는 맞춤 치료 옵션을 제공할 수 있게 되었습니다. 당뇨병 관리 및 첨단 약물 전달 시스템 사용을 장려하는 정부의 이니셔티브와 의료 정책도 펜니들 시장의 성장에 기여하고 있습니다.

조사 대상 기업 예(총 63건)

• Advin Health Care
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Cipla Ltd.
• ARKRAY, Inc.
• Gerresheimer AG
• A. Menarini Diagnostics Srl
• Exelint International Co.
• Hindustan Syringes & Medical Devices Ltd.
• Allison Medical, Inc.
• HTL-Strefa SA
• GlucoRx Ltd.
• Cambridge Sensors Ltd.
• Igaku Needles Private Limited
• AdvaCare Pharma

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 월드 브랜드
• 주요 기업
• 시장 동향과 촉진요인
• 매크로 성장 원동력
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Pen Needles Market to Reach US$4.8 Billion by 2030

The global market for Pen Needles estimated at US$2.6 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Standard Pen Needles, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Safety Pen Needles segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$836.5 Million While China is Forecast to Grow at 10.3% CAGR

The Pen Needles market in the U.S. is estimated at US$836.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$381.7 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Pen Needles Market - Key Trends & Drivers Summarized

Pen needles are essential components used with injection pens to deliver medications such as insulin, growth hormones, and other therapeutic agents. These needles are designed to be attached to the pen device, providing a convenient and precise method for administering subcutaneous injections. Pen needles come in various lengths and gauges, allowing patients and healthcare providers to select the most appropriate needle for different injection sites and patient needs. The design of pen needles focuses on minimizing pain and discomfort during injections, with features such as ultra-thin walls, fine tips, and lubricated coatings. This makes pen needles particularly suitable for patients requiring frequent injections, such as those with diabetes who need regular insulin administration.

Technological advancements have led to significant improvements in the design and functionality of pen needles. Modern pen needles incorporate advanced manufacturing techniques that enhance sharpness and reduce penetration force, resulting in less painful injections. Innovations such as safety pen needles, which feature built-in shields to prevent needlestick injuries, have improved safety for both patients and healthcare providers. Additionally, the development of shorter and finer needles has made injections less intimidating and more comfortable, encouraging better adherence to treatment regimens. The use of high-quality materials ensures the durability and reliability of pen needles, providing consistent performance with each use. These advancements have expanded the adoption of pen needles across various therapeutic areas, making them a preferred choice for medication delivery.

The growth in the pen needles market is driven by several factors, including the rising prevalence of diabetes, increasing adoption of self-administration of medications, and advancements in needle technology. The global increase in diabetes cases has significantly boosted the demand for insulin delivery devices, including pen needles. The trend towards self-administration of medications, driven by patient convenience and the need for regular therapy, has further fueled market growth. Technological advancements, such as the development of safety and ultra-fine pen needles, have enhanced the safety and comfort of injections, encouraging broader adoption among patients. Additionally, the increasing availability of pen needles in various lengths and gauges has provided more options for personalized treatment, catering to diverse patient needs. Government initiatives and healthcare policies promoting diabetes management and the use of advanced drug delivery systems are also contributing to the growth of the pen needles market.

Select Competitors (Total 63 Featured) -

• Advin Health Care
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Cipla Ltd.
• ARKRAY, Inc.
• Gerresheimer AG
• A. Menarini Diagnostics Srl
• Exelint International Co.
• Hindustan Syringes & Medical Devices Ltd.
• Allison Medical, Inc.
• HTL-Strefa SA
• GlucoRx Ltd.
• Cambridge Sensors Ltd.
• Igaku Needles Private Limited
• AdvaCare Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Pen Needles - Global Key Competitors Percentage Market Share in 2024 (E)
  • Pen Needles Competitor Market Share Scenario Worldwide (in %): 2022E
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Needles: A Prelude
  • Types of Needles
  • An Insight into Pen Needles
  • Pen Needles for Insulin Injection
  • Global Market Analysis and Prospects
  • Global Pen Needles Market Set for a Rapid Growth
  • Standard Pen Needles Dominate, Safety Pen Needles to Witness Fastest Growth
  • Emerging Markets: Focal Point for Future Growth
  • Competitive Landscape
  • Top Pen Needle Products
  • Recent Market Activity
• WORLD BRANDS
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Diabetic Population Continues to Drives Demand for Pen Needles
  • World Diabetes and Population Statistics (2019, 2030 & 2045)
  • Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030 and 2045
  • World Diabetes Prevalence (2000-2045P)
  • Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2019 and 2045
  • Global Diabetes Mellitus Population Breakdown by Geographic Region: 2019, 2030 and 2045?
  • Diabetes Emerges as One of the Leading Causes of Mortality
  • Diabetes-Related Deaths as % of Total Deaths in Below 60 Years Population by Region: 2023
  • Growing Prevalence of Chronic Diseases Drive the Demand for Pen Needles
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • High Risk of Diabetes in the Fast Expanding Aging Population Benefit Market Expansion
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Pen Needles Gain Traction as Insulin Pens Rise in Popularity for Administering Insulin
  • Smart Insulin Pens: A Growing Area of Interest
  • Increasing Role of Self-Injection Devices in Diabetes Management
  • Needle-Free Alternatives: A Growing Threat
  • Innovative Technologies Revolutionize Pen Needles Market
  • Advancements in Insulin Delivery Methods Drive the Demand for Pen Needles
  • Advancements in Pen Needle Technology
  • Droplet Micron Insulin Needle Represents Innovation in the Diabetes Supply Market
• MACRO GROWTH DRIVERS
  • Increasing Healthcare Expenditure Aids Pen Drives Market Growth
  • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, 2023
  • Increasing Obesity Levels Underpins Market Growth
  • Average Per Capita Annual Health Expenditure (In US$) due to Obesity
  • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
  • Rising Demand for Biosimilar Drugs Propel the Market for Pen Needles
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Pen Needles Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Market Facts & Figures
  • US Pen Needles Market Share (in %) by Company: 2022 & 2030
  • Standard (Type) Market Share Analysis (in %) of Leading Players in the US for 2022 & 2030
  • Safety (Type) Competitor Revenue Share (in %) in the US: 2022 & 2030
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Market Analytics
  • TABLE 20: USA Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 23: USA Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• JAPAN
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Japan 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• CHINA
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: China 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 41: China Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• EUROPE
  • Market Facts & Figures
  • European Pen Needles Market: Competitor Market Share Scenario (in %) for 2022 & 2030
  • Standard (Type) Market Share (in %) by Company in Europe: 2022 & 2030
  • Safety (Type) Market Share (in %) of Major Players in Europe: 2022 & 2030
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Market Analytics
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Europe 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• FRANCE
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 53: France Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: France Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: France 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• GERMANY
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 59: Germany Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Germany 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 65: Italy Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Italy 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 71: UK Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: UK 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 77: Spain Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Spain 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 83: Russia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Russia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Rest of Europe 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Asia-Pacific 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 104: Australia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Australia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Australia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• INDIA
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 110: India Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: India Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: India 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 113: India Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: South Korea Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: South Korea 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Rest of Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 129: Latin America Historic Review for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Latin America 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Argentina Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Argentina 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Brazil Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Brazil 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Mexico Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Mexico 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Rest of Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Rest of Latin America 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 162: Middle East Historic Review for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Middle East 16-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 170: Iran Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Iran Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Iran 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 176: Israel Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Israel Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Israel 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Saudi Arabia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Saudi Arabia 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 188: UAE Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: UAE Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: UAE 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Rest of Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Rest of Middle East 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030
• AFRICA
  • Pen Needles Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 200: Africa Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Africa Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Africa 16-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2014, 2024 & 2030
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2014, 2024 & 2030

IV. COMPETITION